Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
First Investment: 2018
X‑37 aims to use AI to accelerate small-molecule drug discovery. The company’s seasoned chemists, biologists, and data scientists use machine learning algorithms to identify chemicals with drug-like structures, predict whether they might bind to biological targets, and weed out those likely to have unwanted properties.
Explore Companies
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules